The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Gilead Sciences; Novartis; Roche
Speakers' Bureau - Novartis
Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).
 
Claire N. Harrison
Honoraria - Gilead Sciences; Novartis
Speakers' Bureau - CTI; Gilead Sciences; Novartis; Shire
Research Funding - Novartis
 
Alessandro M. Vannucchi
Consulting or Advisory Role - Novartis
Speakers' Bureau - Gilead Sciences; Novartis; Shire
Research Funding - Novartis
 
Uwe Platzbecker
No Relationships to Disclose
 
Francisco Cervantes
Consulting or Advisory Role - ARIAD; Gilead Sciences; Novartis; Pfizer
Speakers' Bureau - ARIAD; Gilead Sciences; Novartis; Pfizer
 
Vikas Gupta
Honoraria - Incyte; Novartis
Consulting or Advisory Role - Gilead Sciences; Incyte; Novartis
Research Funding - Incyte; Novartis
 
David Lavie
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
 
Francesco Passamonti
No Relationships to Disclose
 
Elliott F. Winton
Consulting or Advisory Role - Gilead Sciences; Incyte
Research Funding - Gilead Sciences; Incyte
 
Hua Dong
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Jun Kawashima
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Julia D. Maltzman
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Jean-Jacques Kiladjian
Honoraria - Novartis; Shire
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; Novartis
Research Funding - AOP Orphan Pharmaceuticals (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Srdan Verstovsek
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CTI BioPharma Corp (Inst); Galena Biopharma (Inst); Genentech (Inst); Geron (Inst); Gilead Sciences (Inst); Incyte (Inst); Lilly (Inst); NS Pharma (Inst); Pfizer (Inst); Promedior (Inst); Roche (Inst); Seagen (Inst)